Joshua Salafsky

Joshua Salafsky is a prominent figure in the biotechnology and pharmaceutical research industry. He is the founder of Skylight Discovery, Inc., a company established in 2021 that provides services to the pharmaceutical industry, focusing on early protein aggregation studies and ligand binding site identification.1

Professional Background

Salafsky's career spans both academia and industry:

Academic Affiliation:: He is currently associated with The Francis Crick Institute, a biomedical research facility in the United Kingdom.2

Education:: Salafsky holds a degree from Stanford University, indicating a strong academic foundation in his field of expertise.2

Entrepreneurial Ventures:: Prior to founding Skylight Discovery, Salafsky was the founder of Biodesy, where he invented the Second Harmonic Generation (SHG) technique for studying biological molecules.4 This demonstrates his innovative approach to scientific research and technology development.

Expertise and Contributions

Salafsky's work primarily focuses on:

• Protein aggregation studies
• Ligand binding site identification
• Development of novel techniques for studying biological molecules

His research has led to publications in scientific journals, with recent work exploring ligand-induced conformational changes in protein molecules.3

Current Role and Company

As the founder of Skylight Discovery, Salafsky leads a company that:

• Is based in Seattle, Washington, USA
• Provides specialized services to the pharmaceutical industry
• Focuses on early-stage drug discovery and protein research

Skylight Discovery is categorized as a new startup with an estimated revenue of 0-1M TTM (Trailing Twelve Months).1

Professional Network

Salafsky maintains a strong professional network, with over 478 connections on LinkedIn.2 His international presence is evident from his work in the United States and his current location in the United Kingdom.

Joshua Salafsky's career trajectory showcases a blend of scientific expertise, entrepreneurial spirit, and leadership in the biotechnology sector, positioning him as a notable figure in the field of protein research and drug discovery.